{"id":"vehicle-control","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vehicle controls contain the same inactive ingredients and excipients as the active drug formulation but without the active pharmaceutical ingredient. They are used in comparative studies to isolate the true pharmacological effect of the drug from effects caused by the delivery system, excipients, or non-specific factors. This is a standard research tool rather than a therapeutic agent.","oneSentence":"A vehicle control is an inert formulation used as a negative control in clinical studies to establish baseline effects and distinguish drug-specific activity from placebo or formulation effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:15:07.214Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT03372811","phase":"PHASE2","title":"Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-IIb Trial)","status":"COMPLETED","sponsor":"Psoriasis Research Institute of Guangzhou","startDate":"2015-06-11","conditions":"Psoriasis Vulgaris, Topical Administration","enrollment":88},{"nctId":"NCT06135415","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2023-12-21","conditions":"Keratosis, Actinic","enrollment":280},{"nctId":"NCT04499248","phase":"PHASE1, PHASE2","title":"AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"AbbVie","startDate":"2020-11-16","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":96},{"nctId":"NCT07487363","phase":"PHASE1, PHASE2","title":"TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-05","conditions":"Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction","enrollment":80},{"nctId":"NCT05713877","phase":"PHASE2","title":"Melatonin for Treatment of Delirium in Critically Ill Adult Patients","status":"RECRUITING","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2023-02-01","conditions":"Delirium","enrollment":30},{"nctId":"NCT05295732","phase":"PHASE3","title":"The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis","status":"COMPLETED","sponsor":"Timber Pharmaceuticals Inc.","startDate":"2022-06-21","conditions":"Ichthyosis","enrollment":153},{"nctId":"NCT07482787","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa","status":"NOT_YET_RECRUITING","sponsor":"Paradigm Therapeutics","startDate":"2026-05-15","conditions":"Epidermolysis Bullosa (EB)","enrollment":80},{"nctId":"NCT05608681","phase":"PHASE1, PHASE2","title":"A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).","status":"RECRUITING","sponsor":"Eupraxia Pharmaceuticals Inc.","startDate":"2023-03-31","conditions":"Eosinophilic Esophagitis","enrollment":117},{"nctId":"NCT07479043","phase":"PHASE3","title":"To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress Syndrome (ARDS).","status":"NOT_YET_RECRUITING","sponsor":"Breathe Biologics, Inc.","startDate":"2026-07","conditions":"Acute Respiratory Distress Syndrome","enrollment":128},{"nctId":"NCT07257029","phase":"PHASE2","title":"Topical Ketotifen 0.25% for Secondary Vestibulodynia","status":"RECRUITING","sponsor":"Center for Vulvovaginal Disorders","startDate":"2026-01-02","conditions":"Provoked Vestibulodynia, Secondary Provoked Vestibulodynia, Vulvodynia","enrollment":54},{"nctId":"NCT05910450","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cassiopea SpA","startDate":"2023-06-21","conditions":"Alopecia, Androgenetic","enrollment":703},{"nctId":"NCT06789861","phase":"PHASE1","title":"A First in Human Study of TT5 in Single and Multiple Ascending Doses in Healthy Volunteers and Surgical Patients","status":"RECRUITING","sponsor":"Tafalgie Therapeutics","startDate":"2025-05-23","conditions":"Pain","enrollment":94},{"nctId":"NCT07196332","phase":"NA","title":"Recovering Sleep After Trauma","status":"NOT_YET_RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2026-04-01","conditions":"Post-traumatic Stress Disorder","enrollment":20},{"nctId":"NCT05521438","phase":"PHASE2, PHASE3","title":"Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Quoin Pharmaceuticals","startDate":"2022-06-23","conditions":"Netherton Syndrome","enrollment":30},{"nctId":"NCT07199660","phase":"NA","title":"Reactions to Social Media Warning Labels Among Teens and Young Adults","status":"COMPLETED","sponsor":"Stanford University","startDate":"2025-12-02","conditions":"Screen Time Exposure","enrollment":1012},{"nctId":"NCT06568627","phase":"PHASE3","title":"A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)","status":"RECRUITING","sponsor":"MediWound Ltd","startDate":"2025-06-01","conditions":"Venous Leg Ulcer (VLU)","enrollment":216},{"nctId":"NCT07265479","phase":"PHASE3","title":"A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis","status":"RECRUITING","sponsor":"Organon and Co","startDate":"2025-12-29","conditions":"Atopic Dermatitis","enrollment":180},{"nctId":"NCT06958211","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-12","conditions":"Hidradenitis Suppurativa","enrollment":550},{"nctId":"NCT06959225","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-23","conditions":"Hidradenitis Suppurativa","enrollment":550},{"nctId":"NCT03104517","phase":"PHASE3","title":"Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cook MyoSite","startDate":"2019-04-23","conditions":"Stress Urinary Incontinence","enrollment":96},{"nctId":"NCT07469228","phase":"PHASE1","title":"A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2025-08-04","conditions":"Acne Vulgaris","enrollment":1043},{"nctId":"NCT07128628","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease","status":"RECRUITING","sponsor":"Bausch & Lomb Incorporated","startDate":"2025-10-24","conditions":"Dry Eye Disease","enrollment":423},{"nctId":"NCT05776277","phase":"PHASE3","title":"Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cook MyoSite","startDate":"2024-03-21","conditions":"Fecal Incontinence","enrollment":200},{"nctId":"NCT06542497","phase":"PHASE3","title":"Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2024-08-15","conditions":"Presbyopia","enrollment":569},{"nctId":"NCT05646719","phase":"PHASE3","title":"Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2022-12-22","conditions":"Presbyopia","enrollment":333},{"nctId":"NCT06349759","phase":"PHASE3","title":"Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2024-04-01","conditions":"Mesopic Vision, Night Vision Loss","enrollment":200},{"nctId":"NCT06053138","phase":"NA","title":"Assessment of BHB Concentration Agreement Among Sampling Locations and the Impact of Ketosis on EPO, and More","status":"COMPLETED","sponsor":"Central Jutland Regional Hospital","startDate":"2023-08-24","conditions":"Ketosis","enrollment":16},{"nctId":"NCT07453888","phase":"PHASE3","title":"Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)","status":"NOT_YET_RECRUITING","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2026-03","conditions":"Non-Arteritic Anterior Ischemic Optic Neuropathy","enrollment":272},{"nctId":"NCT07076784","phase":"NA","title":"Topical Icariin on Acne and Acne Scars","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2023-03-21","conditions":"Acne, Acne Scars","enrollment":25},{"nctId":"NCT07144345","phase":"PHASE3","title":"Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2025-11-19","conditions":"Actinic Keratosis","enrollment":160},{"nctId":"NCT07447141","phase":"PHASE1","title":"DBM-1152A Inhalation Solution in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"Joincare Pharmaceutical Group Industry Co., Ltd","startDate":"2023-12-24","conditions":"Health, Health Adult Subjects","enrollment":44},{"nctId":"NCT07369869","phase":"NA","title":"Evaluating the Effects of Nutritional Interventions on Sleep, the Gut Microbiome, Cognition, and Stress.","status":"NOT_YET_RECRUITING","sponsor":"Northumbria University","startDate":"2026-05","conditions":"Stress, Sleep, Cognition","enrollment":68},{"nctId":"NCT05171894","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT","status":"RECRUITING","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","startDate":"2024-09-21","conditions":"Port-wine Birthmarks, Port-Wine Stain, Nevus Flammeus","enrollment":84},{"nctId":"NCT07443202","phase":"PHASE2","title":"Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)","status":"ENROLLING_BY_INVITATION","sponsor":"Tarsus Pharmaceuticals, Inc.","startDate":"2025-12-05","conditions":"Ocular Rosacea","enrollment":155},{"nctId":"NCT07437586","phase":"PHASE2","title":"Topical GHK-Cu Gel for Acute Skin Wound Healing","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-02","conditions":"Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds)","enrollment":60},{"nctId":"NCT07439419","phase":"PHASE1","title":"DBM-1152A Inhalation Solution in Healthy Volunteers","status":"COMPLETED","sponsor":"Joincare Pharmaceutical Group Industry Co., Ltd","startDate":"2024-08-18","conditions":"Healthy","enrollment":20},{"nctId":"NCT06999733","phase":"PHASE1, PHASE2","title":"A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis","status":"RECRUITING","sponsor":"Krystal Biotech, Inc.","startDate":"2025-07-07","conditions":"Neurotrophic Keratitis","enrollment":60},{"nctId":"NCT07430917","phase":"PHASE2","title":"Safety and Efficacy of J147 in Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Abrexa Pharmaceuticals, Inc.","startDate":"2026-03-20","conditions":"Acute Ischemic Stroke","enrollment":196},{"nctId":"NCT07431476","phase":"PHASE4","title":"Brimonidine 0.33% for Rosacea-Related Facial Erythema","status":"COMPLETED","sponsor":"Istanbul Training and Research Hospital","startDate":"2025-05-01","conditions":"Rosacea, Rosacea Subtype 1 (Erythematotelangiectatic)","enrollment":45},{"nctId":"NCT07426120","phase":"PHASE3","title":"Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)","status":"RECRUITING","sponsor":"Psoriasis Research Institute of Guangzhou","startDate":"2026-02-01","conditions":"Psoriasis Vulgaris, Topical Administration, Phase III","enrollment":300},{"nctId":"NCT04317664","phase":"PHASE3","title":"Intervention to Improve Driving Practices Among High-Risk Teen Drivers","status":"COMPLETED","sponsor":"Ginger Yang","startDate":"2020-09-28","conditions":"Drive, Recidivism, Communication","enrollment":240},{"nctId":"NCT07335588","phase":"PHASE3","title":"A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus","status":"NOT_YET_RECRUITING","sponsor":"LEO Pharma","startDate":"2026-05-06","conditions":"Lichen Sclerosus","enrollment":652},{"nctId":"NCT07144852","phase":"PHASE3","title":"Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2025-11-29","conditions":"Actinic Keratosis","enrollment":260},{"nctId":"NCT05662202","phase":"PHASE3","title":"Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biofrontera Inc.","startDate":"2022-12-12","conditions":"Actinic Keratoses","enrollment":172},{"nctId":"NCT07281014","phase":"PHASE4","title":"Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing","status":"RECRUITING","sponsor":"Yale University","startDate":"2026-01-27","conditions":"Heart Failure","enrollment":20},{"nctId":"NCT06678022","phase":"NA","title":"Use of Unmanned Air Vehicles (Medical Drones) to Overcome Geographical Barriers to Delivery of Anti-Retroviral Therapy and Biological Samples","status":"RECRUITING","sponsor":"Makerere University","startDate":"2025-03-18","conditions":"HIV, Viral Load","enrollment":1086},{"nctId":"NCT07412496","phase":"PHASE2","title":"A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive Keratectomy","status":"NOT_YET_RECRUITING","sponsor":"Bausch & Lomb Incorporated","startDate":"2026-04","conditions":"Pain, Postoperative","enrollment":123},{"nctId":"NCT05005845","phase":"PHASE2","title":"NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)","status":"COMPLETED","sponsor":"NFlection Therapeutics, Inc.","startDate":"2021-09-29","conditions":"Cutaneous Neurofibroma, Neurofibromatosis 1","enrollment":199},{"nctId":"NCT06244316","phase":"PHASE2","title":"A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2024-01-22","conditions":"Dry Eye Disease","enrollment":317},{"nctId":"NCT07286487","phase":"NA","title":"Glycyrrhetinic Acid and Acute Irritant Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of Split, School of Medicine","startDate":"2026-03-01","conditions":"Irritant Contact Dermatitis","enrollment":30},{"nctId":"NCT07264517","phase":"PHASE2","title":"Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).","status":"RECRUITING","sponsor":"Instituto Grifols, S.A.","startDate":"2025-11-03","conditions":"Dry Eye Disease","enrollment":100},{"nctId":"NCT03928184","phase":"PHASE3","title":"Patient-Reported and Radiographic Outcomes in Evaluating Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis","status":"COMPLETED","sponsor":"Biosplice Therapeutics, Inc.","startDate":"2019-05-17","conditions":"Knee Osteoarthritis","enrollment":501},{"nctId":"NCT03972592","phase":"PHASE2","title":"Topical Sirolimus in Cutaneous Lymphatic Malformations","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2019-06-05","conditions":"Vascular Malformations, Lymphatic Malformation","enrollment":55},{"nctId":"NCT06400459","phase":"PHASE1, PHASE2","title":"IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"IVIEW Therapeutics Inc.","startDate":"2024-06-25","conditions":"Dry Eye Disease","enrollment":150},{"nctId":"NCT06830863","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity","status":"RECRUITING","sponsor":"Azitra Inc.","startDate":"2025-08-25","conditions":"EGFR Inhibitor-associated Rash","enrollment":32},{"nctId":"NCT07401628","phase":"NA","title":"In-Vehicle Real-Time Cannabis Influenced Driving Detection","status":"RECRUITING","sponsor":"University of Bern","startDate":"2026-01-05","conditions":"Driving Under the Influence, Cannabis-impaired Driving","enrollment":45},{"nctId":"NCT03954236","phase":"PHASE2","title":"Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-05-14","conditions":"Non-sclerotic Cutaneous Chronic Graft-versus-host Disease","enrollment":24},{"nctId":"NCT02581085","phase":"PHASE2","title":"Tocotrienol Against the Progression of End Stage Liver Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chandan Sen","startDate":"2019-11-01","conditions":"End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis, NAFLD - Nonalcoholic Fatty Liver Disease","enrollment":70},{"nctId":"NCT07395232","phase":"PHASE3","title":"An Efficacy and Safety Study of DFL24498 in the Treatment of AKC","status":"RECRUITING","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2025-12-01","conditions":"Atopic Keratoconjunctivitis","enrollment":138},{"nctId":"NCT07370584","phase":"PHASE1","title":"A Safety Study of IVMED-85 Ophthalmic Solution in Healthy Adults","status":"RECRUITING","sponsor":"iVeena Delivery Systems, Inc.","startDate":"2026-02-04","conditions":"Safety Study","enrollment":36},{"nctId":"NCT07118241","phase":"PHASE2","title":"A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE","status":"RECRUITING","sponsor":"Lubris Bio Pty Ltd","startDate":"2025-09-17","conditions":"Sjögren's Syndrome","enrollment":80},{"nctId":"NCT02633163","phase":"PHASE2","title":"Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2018-11-18","conditions":"Systemic Lupus Erythematosus","enrollment":81},{"nctId":"NCT06137157","phase":"PHASE1","title":"Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome","status":"RECRUITING","sponsor":"Azitra Inc.","startDate":"2024-06-19","conditions":"Netherton Syndrome","enrollment":12},{"nctId":"NCT07382427","phase":"PHASE2","title":"A Phase 2 Study to Assess the Effectiveness of Topical Terbinafine in Participants With Mild to Moderate Onychomycosis of the Toenails","status":"NOT_YET_RECRUITING","sponsor":"Onyx Axiom","startDate":"2026-03","conditions":"Onychomycosis of Toenail","enrollment":200},{"nctId":"NCT04385303","phase":"PHASE3","title":"Patient-Reported Outcomes in Evaluating Lorecivivint (SM04690) for Moderate to Severe Knee Osteoarthritis (STRIDES-1)","status":"COMPLETED","sponsor":"Biosplice Therapeutics, Inc.","startDate":"2020-05-26","conditions":"Knee Osteoarthritis","enrollment":496},{"nctId":"NCT07352800","phase":"PHASE2","title":"Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia","status":"RECRUITING","sponsor":"Aplagon Oy","startDate":"2026-01-29","conditions":"Peripheral Arterial Occlusive Disease, Chronic Limb-Threatening Ischemia","enrollment":42},{"nctId":"NCT06919081","phase":"PHASE2","title":"Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-08-01","conditions":"Persistent Corneal Epithelial Defect, Corneal Epithelial Disorders","enrollment":24},{"nctId":"NCT07377097","phase":"NA","title":"Effects of Sweetener Consumption on Risk Factors for Heart Disease in Prediabetic Subjects","status":"NOT_YET_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2026-01-05","conditions":"Prediabetic State, Metabolic Syndrome, Insulin Resistance","enrollment":80},{"nctId":"NCT06594393","phase":"PHASE2","title":"A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study","status":"RECRUITING","sponsor":"Xinnate AB","startDate":"2026-01-30","conditions":"Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa","enrollment":32},{"nctId":"NCT05212246","phase":"PHASE3","title":"Basal Cell Carcinoma Chemoprevention Trial","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-05-01","conditions":"Basal Cell Carcinoma","enrollment":1630},{"nctId":"NCT07355075","phase":"PHASE2","title":"A Study to Assess the Efficacy of GX-03 in Moderate to Severe Eczema (Atopic Dermatitis)","status":"RECRUITING","sponsor":"Turn Therapeutics","startDate":"2025-07-11","conditions":"Eczema Atopic Dermatitis, Eczema, Atopic Dermatitis","enrollment":100},{"nctId":"NCT06538662","phase":"PHASE3","title":"An Investigation of FID 123320 for the Reduction of Ocular Redness in Pediatric and Adult Populations","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2024-10-07","conditions":"Ocular Redness, Eye Irritation","enrollment":283},{"nctId":"NCT07357870","phase":"PHASE1","title":"A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo","status":"RECRUITING","sponsor":"CAGE Bio Inc.","startDate":"2025-07-25","conditions":"Vitiligo","enrollment":36},{"nctId":"NCT07246590","phase":"PHASE3","title":"Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)","status":"RECRUITING","sponsor":"Verrica Pharmaceuticals Inc.","startDate":"2025-12-17","conditions":"Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV)","enrollment":300},{"nctId":"NCT07118254","phase":"PHASE2","title":"A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)","status":"RECRUITING","sponsor":"Lubris Bio Pty Ltd","startDate":"2025-09-17","conditions":"Ocular Graft Versus Host Disease","enrollment":15},{"nctId":"NCT05411367","phase":"PHASE3","title":"A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye","status":"COMPLETED","sponsor":"Seikagaku Corporation","startDate":"2022-07-28","conditions":"Dry Eye Disease","enrollment":232},{"nctId":"NCT07345390","phase":"PHASE2","title":"Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne Vulgaris","status":"NOT_YET_RECRUITING","sponsor":"Jiangxi Kvvit Pharmaceutical Co., Ltd.","startDate":"2026-01-10","conditions":"Acne Vulgaris","enrollment":180},{"nctId":"NCT03918915","phase":"PHASE3","title":"The Safety and Efficacy of SYD-101 in Children With Myopia","status":"COMPLETED","sponsor":"Sydnexis, Inc.","startDate":"2019-04-24","conditions":"Nearsightedness, Near Sightedness, Near-sightedness","enrollment":852},{"nctId":"NCT03483246","phase":"PHASE3","title":"Impact of Fecal Microbiota Transplantation in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-09-17","conditions":"Ulcerative Colitis","enrollment":150},{"nctId":"NCT07071610","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of LNK01004 Ointment in Adults With Atopic Dermatitis","status":"COMPLETED","sponsor":"Lynk Pharmaceuticals Co., Ltd","startDate":"2025-03-18","conditions":"Atopic Dermatitis","enrollment":75},{"nctId":"NCT03573401","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biofrontera Inc.","startDate":"2018-09-25","conditions":"Superficial Basal Cell Carcinoma","enrollment":187},{"nctId":"NCT06559774","phase":"NA","title":"The Hastiin Bidziil (Strong Man) Intervention","status":"RECRUITING","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2025-06-18","conditions":"Substance Use","enrollment":160},{"nctId":"NCT03727022","phase":"PHASE2","title":"Safety and Bone Health Study of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis","status":"COMPLETED","sponsor":"Biosplice Therapeutics, Inc.","startDate":"2018-11-28","conditions":"Knee Osteoarthritis","enrollment":101},{"nctId":"NCT06047717","phase":"NA","title":"Vision Loss Impact on Navigation in Virtual Reality","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2023-11-28","conditions":"Stroke, Ischemic, Quadrantanopia, Hemianopsia, Homonymous","enrollment":40},{"nctId":"NCT06954597","phase":"PHASE2","title":"Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis","status":"RECRUITING","sponsor":"Topadur Pharma AG","startDate":"2025-02-04","conditions":"Digital Ulcers in Systemic Sclerosis","enrollment":15},{"nctId":"NCT05361733","phase":"PHASE1","title":"A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers.","status":"NOT_YET_RECRUITING","sponsor":"Xfibra, Inc.","startDate":"2026-01-15","conditions":"Focus of the Study: Safety of XFB19","enrollment":40},{"nctId":"NCT07005180","phase":"PHASE2","title":"Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"Hillhurst Biopharmaceuticals, Inc.","startDate":"2026-02-28","conditions":"Parkinson Disease","enrollment":36},{"nctId":"NCT07321834","phase":"PHASE2","title":"A Study to Evaluate AI-09 In Participants With Glabellar Lines","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eirion Therapeutics Inc.","startDate":"2025-12-03","conditions":"Glabellar Lines","enrollment":68},{"nctId":"NCT06400511","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment","status":"TERMINATED","sponsor":"Famy Life Sciences, a Viatris Company","startDate":"2024-04-22","conditions":"Blepharitis","enrollment":477},{"nctId":"NCT07319117","phase":"NA","title":"Evaluation of the Impact of a Nutritional Formulation on Cognitive Performance Following Stress Exposure.","status":"RECRUITING","sponsor":"Leeds Beckett University","startDate":"2025-12-15","conditions":"Cognitive Assessment, Working Memory, Executive Function (Cognition)","enrollment":40},{"nctId":"NCT05514340","phase":"PHASE2","title":"Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy","status":"RECRUITING","sponsor":"Pharmazz, Inc.","startDate":"2023-09-06","conditions":"Hypoxic-Ischemic Encephalopathy, Neonatal Asphyxia, Neonatal Encephalopathy","enrollment":40},{"nctId":"NCT05691244","phase":"PHASE3","title":"Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke","status":"RECRUITING","sponsor":"Pharmazz, Inc.","startDate":"2025-07-24","conditions":"Acute Ischemic Stroke, Cerebral Stroke","enrollment":514},{"nctId":"NCT05251181","phase":"PHASE3","title":"A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent","status":"NOT_YET_RECRUITING","sponsor":"Pharmazz, Inc.","startDate":"2026-02","conditions":"Hypovolemic Shock","enrollment":430},{"nctId":"NCT07287033","phase":"PHASE1","title":"Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy","status":"RECRUITING","sponsor":"Mabylon AG","startDate":"2025-12-06","conditions":"Peanut Allergies","enrollment":48},{"nctId":"NCT06899230","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007","status":"ACTIVE_NOT_RECRUITING","sponsor":"iQure Australia Pty Ltd","startDate":"2025-04-08","conditions":"Drug Resistant Epilepsy, Focal Seizure","enrollment":72},{"nctId":"NCT07301515","phase":"NA","title":"Randomised Controlled Trial of an Antioxidant and Sunscreen Combination Cream for Reducing DNA Damage in Human Skin","status":"COMPLETED","sponsor":"Klira Skin","startDate":"2025-03-01","conditions":"Photoaging, Photodamage, Mitochondrial Damage","enrollment":52},{"nctId":"NCT05555589","phase":"PHASE3","title":"Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2","status":"RECRUITING","sponsor":"ReGenTree, LLC","startDate":"2023-04-11","conditions":"Neurotrophic Keratopathy","enrollment":70},{"nctId":"NCT07299058","phase":"NA","title":"The Effect of a Guessing Game on Fear, Pain, and Emotional State During Blood Collection in Children Aged 6-12","status":"NOT_YET_RECRUITING","sponsor":"Dokuz Eylul University","startDate":"2025-12-20","conditions":"Pain, Blood Sampling Procedure, Fear Anxiety","enrollment":70},{"nctId":"NCT04845620","phase":"PHASE3","title":"Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-04-07","conditions":"Atopic Dermatitis Eczema","enrollment":652},{"nctId":"NCT06493604","phase":"PHASE3","title":"A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2024-06-24","conditions":"Dry Eye Disease","enrollment":116}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8029,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vehicle","Placebo","placebo"],"phase":"marketed","status":"active","brandName":"Vehicle control","genericName":"Vehicle control","companyName":"University of Reading","companyId":"university-of-reading","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}